The T Cell Immunoreceptor With Ig And ITIM Domains pipeline drugs market research report outlays comprehensive information on the T Cell Immunoreceptor With Ig And ITIM Domains targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the T Cell Immunoreceptor With Ig And ITIM Domains pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Undisclosed, and Musculoskeletal Disorders which include the indications Solid Tumor, Non-Small Cell Lung Cancer, Unspecified, and Arthritis. It also reviews key players involved in T Cell Immunoreceptor With Ig And ITIM Domains targeted therapeutics development with respective active and dormant or discontinued products.
The T Cell Immunoreceptor With Ig And ITIM Domains pipeline targets constitutes close to 66 molecules. Out of which, approximately 65 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 6, 13, 14, 1, 27, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
T Cell Immunoreceptor With Ig And ITIM Domains overview
T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an immune checkpoint receptor that plays a crucial role in regulating T cell and natural killer (NK) cell function. It is expressed on the surface of activated T cells and NK cells and interacts with its ligands, CD155 (poliovirus receptor-related protein 1, PVR1), CD112 (nectin-like protein 2, PVRL2), and CD113 (PVRL3), to deliver inhibitory signals and dampen immune responses.
For a complete picture of T Cell Immunoreceptor With Ig And ITIM Domains’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
